Qulipta (atogepant) works by blocking a specific protein receptor in the brain and nervous system that plays a central role in triggering migraine attacks. It’s a daily pill taken to prevent migraines before they start, not to treat them once they’ve begun. Understanding what it blocks, and why that matters, helps explain how a single tablet each day can meaningfully reduce the number of migraine days you experience each month.
The Protein Behind Migraine Pain
The key player is a signaling molecule called CGRP, short for calcitonin gene-related peptide. During a migraine, nerve fibers release large amounts of CGRP, which then locks onto receptors on nearby blood vessels and nerve cells. When CGRP attaches to its receptor, it sets off a chain reaction: blood vessels in the brain dilate, surrounding tissue becomes inflamed, and pain-sensing nerves become hypersensitive. This cascade is what produces the throbbing, often debilitating pain of a migraine, along with sensitivity to light, sound, and nausea.
People who get frequent migraines tend to have elevated CGRP levels even between attacks. That persistent signaling keeps the nervous system in a hair-trigger state, making it easier for the next migraine to fire. This is why blocking CGRP at the receptor level, rather than just treating pain after the fact, can reduce how often migraines occur.
How Qulipta Blocks the Signal
Qulipta is a competitive antagonist of the CGRP receptor. In practical terms, it sits in the same binding pocket on the receptor where CGRP would normally attach, physically preventing the molecule from docking. With CGRP locked out, the downstream chain reaction never starts: blood vessels don’t dilate abnormally, inflammation doesn’t flare, and pain nerves don’t become sensitized.
The CGRP receptor itself is made up of three components that work together. Qulipta targets the assembled receptor at the site where the CGRP molecule would normally bind, making it highly selective. It doesn’t interfere broadly with other signaling systems in the brain, which is part of why the side effect profile is relatively mild compared to older preventive migraine medications like beta-blockers or antidepressants.
How Well It Reduces Migraine Days
The clearest picture of Qulipta’s effectiveness comes from the ADVANCE trial, which tested three doses (10 mg, 30 mg, and 60 mg) against placebo over 12 weeks. In the first four weeks, people taking the 60 mg dose experienced about 3.9 fewer migraine days per month compared to baseline, while the placebo group saw a reduction of 1.6 days. Even the lowest 10 mg dose produced a reduction of 3.1 days, roughly double the placebo effect.
The benefit grew slightly over time. By weeks 9 through 12, monthly migraine days dropped by 4.2 to 4.4 across all three Qulipta doses, compared to 3.0 for placebo. Importantly, the improvement appeared within the first month and held steady throughout the study, so you don’t need to wait several months to know if it’s working for you. If your migraine frequency hasn’t improved after the first few weeks, that’s useful information for a conversation with your provider about adjusting the approach.
Prevention Only, Not a Rescue Medication
Qulipta is approved specifically for migraine prevention, both episodic (fewer than 15 headache days per month) and chronic (15 or more). This is an important distinction because other drugs in the same gepant class serve different purposes. Ubrelvy, for instance, is taken only when a migraine hits to stop the attack in progress. Nurtec ODT does double duty, approved for both treating active migraines and preventing episodic ones.
Qulipta is taken once daily as a swallowed tablet, regardless of whether you feel a migraine coming on. The goal is to keep the CGRP receptor consistently blocked so that attacks are less likely to develop in the first place. You take it the same way every day, with or without food.
Common Side Effects
The most frequently reported side effects are digestive. In clinical trials, nausea occurred in 5% to 9% of people taking Qulipta depending on the dose, compared to 3% on placebo. Constipation showed a similar pattern: 6% to 8% on Qulipta versus 2% on placebo. Fatigue was less clearly dose-related, affecting about 4% to 5% of people on Qulipta versus 4% on placebo.
Higher doses tend to produce more nausea and constipation, which is one reason providers sometimes start at a lower dose. For most people, these side effects are mild and manageable. Earlier generations of oral CGRP-blocking drugs were shelved during development because they caused serious liver damage. Qulipta was studied extensively for this, and liver enzyme elevations occurred at the same rate as placebo (about 1%). The few cases that were possibly linked to the drug were all mild, caused no symptoms, and resolved quickly after stopping the medication. Routine liver monitoring isn’t required.
Dose Adjustments and Drug Interactions
Qulipta is available in 10 mg, 30 mg, and 60 mg tablets. The standard dose for episodic migraine is 10 mg or 30 mg once daily, while the chronic migraine dose is 60 mg once daily. However, certain medications change how your body processes Qulipta, requiring a lower dose.
If you take a strong CYP3A4 inhibitor, a category that includes certain antifungal medications, some antibiotics, and several HIV treatments, the recommended Qulipta dose drops to 10 mg once daily for both episodic and chronic migraine. These drugs slow the breakdown of Qulipta in your body, effectively increasing its concentration in your bloodstream. Your prescriber will know if any of your current medications fall into this category.
Kidney function also matters. For episodic migraine in people with severe kidney impairment, the dose is reduced to 10 mg daily. For chronic migraine, Qulipta should be avoided entirely in people with severe kidney impairment or end-stage kidney disease, because the drug can’t be cleared efficiently enough to maintain safe levels.
How Qulipta Compares to Other Gepants
All three oral gepants on the market, Qulipta, Nurtec ODT, and Ubrelvy, block the same CGRP receptor. The differences lie in how they’re used and how they interact with other drugs. Ubrelvy is purely a rescue medication for active attacks. Nurtec ODT dissolves on the tongue and is approved for both acute treatment and episodic migraine prevention. Qulipta is the only one designed exclusively for daily prevention across both episodic and chronic migraine.
Drug interactions also differ between the three. Qulipta requires dose changes with a specific class of liver enzyme inhibitors called OATP inhibitors, while Nurtec and Ubrelvy require adjustments with a different set of transporters. This can matter if you’re on multiple medications, because one gepant may fit better with your existing prescriptions than another.